Product Images Kadcyla

This is a survival analysis of patients (n=496) treated with ado-trastuzumab emtansine compared to lapatinib plus capecitabine. The analysis compares the duration of survival in months and shows the number of patients at risk along the way. The hazard ratio and p-value are estimated using a stratified Cox model and log-rank test, respectively. The text seems to be presenting a graph or a chart; however, only the text information extractable from the graphic is given, and the graph's image is not available.*

Kadcyla is a medication that requires intravenous infusion. This medication comes in a single-dose vial with a strength of 100 mg. Prior to administration, the medication must be reconstituted and diluted. Any unused portion of the product in the single-dose vial should be discarded. Kadcyla must be kept refrigerated. The manufacturer of this medication is Genentech and the product is identified by the National Drug Code (NDC) number 50242-088-01.*

Kadcyla® (ado-trastuzumab emtansine) is a medication that is administered through intravenous infusion only. It comes in a single-dose vial containing 160 mg per vial. The medication should be reconstituted and diluted before administration. Any unused portion should be discarded. The medication should be refrigerated and the given NDC code is 50242-087-01.*